IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026
PR Newswire•13/10/2026•08:05 ET
1
Key Highlights
- ➤97.5% objective response rate at 12 months with cryoablation plus endocrine therapy
- ➤91.7% objective response rate at 12 months with cryoablation alone
- ➤ProSense featured in two EUSOBI scientific sessions on breast intervention
- ➤Two ProSense workshops each attracted nearly 70 participants
- ➤ProSense posters highlighted Romanian outcomes and CEM response prediction
Expert Statements
Eyal Shamir, Chief Executive Officer of IceCure Medical
“We are thrilled by the tremendous enthusiasm and engagement ProSense(® )generated throughout EUSOBI”
Eyal Shamir, Chief Executive Officer of IceCure Medical
“From live demonstrations and two key scientific sessions to two workshops attended by nearly 70 participants each, the response was outstanding.”
Eyal Shamir, Chief Executive Officer of IceCure Medical
“The inclusion of ProSense(® )in scientific posters and the presentation of encouraging 12-month clinical results further demonstrate the growing momentum behind breast cancer cryoablation and the expanding role of ProSense(® )in advancing minimally invasive care across Europe.”
IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026 PR Newswire
Scientific presentations, research posters and clinical workshops featured ProSense(® )breast cancer cryoablation and highlighted strong physician engagement across Europe
Get started
Create a free account to read the full story.